Group items matching

in title, tags, annotations or url

Southwark Crown Court on Thursday sentenced two pharmacists to two years of imprisonment each, suspended for 24 months, after they were found guilty of selling 'industrial' quantities of Class C controlled drugs. Mandip Sidhu (47) of Littleover, Derby and Nabeil Nasr (42) of Cheadle, Greater Manchester, pleaded guilty at an earlier hearing following an investigation by the Criminal Enforcement Unit of the Medicines and Healthcare Products Regulatory Authority (MHRA). Both Sidhu and Nasr were pharmacists registered with the General Pharmaceutical Council at the time of the offenses, which took place between May 2013 and June 2017. Sidhu was the director of Pharmaceutical Health Limited (PHL) in Derby, while Nasr owned several pharmacies across the North West of England. Sidhu was sentenced to two years imprisonment on each of five counts of supplying Class C drugs and four months for forgery, all to run concurrently and suspended for 24 months. Additionally, she must complete 200 hours of community service for her role in the illegal supply of diazepam, zolpidem, and zopiclone.

We're approaching that time of year where the sun is supposed to be shinning and things are supposed to quieten down over the summer holidays (note I said supposed to. . . well we have the sun at least). The elections are over, and a new party is in power. Wes Streeting is the Secretary of State for Health and Social Care. He's met with GPs and Dentists and has great ambitions for Primary Care but when will he meet with community pharmacists? To be fair to Wes, he did visit a local pharmacy in his constituency, with CPNEL last year as Shadow Health Secretary (and was a guest speaker at the Pharmacy Business Awards 2023). He has also had meetings with NPA and CPE, so we know he understands the value of Community Pharmacy. The question is, do we as a sector and profession need to shout louder so that we aren't forgotten about, as healthcare plans are being drawn up? Community Pharmacy is a humble sector, not unlike most other HC sectors. The difference is that we often get forgotten. I have lost count of the times I've heard in meetings or conversations "Primary care and community pharmacy. . ." totally disregarding the fact that we are part of primary care.

Want to lose weight? Eat breakfast at seven.11 am and dinner at 6:14 pm

P3 Healthcare Services is offering the services upon which the medical practitioners can count. On the platform of P3 Healthcare Solutions, the providers can get transparent reporting tools and simplified methods of billing and coding processes

American pharmaceutical giant Pfizer has received marketing authorisation from the Medicines and Healthcare products Regulatory Agency (MHRA) for its medication Etrasimod, marketed as Velsipity, used to treat people with moderately to severely active ulcerative colitis. Ulcerative colitis (UC) is a type of inflammatory bowel disease (IBD) that causes inflammation and ulcers (sores) in the lining of the large intestine (colon) and rectum. The approved recommended dose for Velsipity is one 2 mg tablet to be taken once daily. For the first three days, it is advised to take the medication with food, and subsequently, it can be taken daily either with or without food. According to the regulator, the approval of the medication is based on evidence from two clinical studies, which showed that 26 per cent of patients taking etrasimod achieved clinical remission after 12 weeks of treatment compared with 11 per cent of those receiving placebo. The studies included more than 740 patients aged 16 years and over for whom standard treatment or other treatments did not work well enough or could not be used.